阿帕替尼联合奥沙利铂、雷替曲塞方案对晚期结直肠癌的应用效果分析  

Effect of Apatinib Combined with Oxaliplatin and Raltitrexed in the Treatment of Advanced Colorectal Cancer

作　　者：孙鸿燕 许永春 李志晋 黄勇亮 马曦 SUN Hongyan;XU Yongchun;LI Zhijin;HUANG Yongliang;MA Xi(Department of Gastroenterology,908th Hospital of Joint Logistics Support Force,Nanchang,Jiangxi 330002,China)

机构地区：[1]联勤保障部队第九〇八医院消化内科,江西南昌330002

出　　处：《转化医学杂志》2024年第4期628-631,共4页Translational Medicine Journal

基　　金：江西省中医药科技计划一般项目(2023B0263)。

摘　　要：目的探讨阿帕替尼联合RALOX(奥沙利铂+雷替曲塞)方案对晚期结直肠癌的应用效果。方法选取在联勤保障部队第九〇八医院消化内科采用阿帕替尼联合RALOX方案(观察组,n=39)或单用RALOX方案(对照组,n=39)治疗的晚期结直肠癌患者,比较阿帕替尼联合RALOX方案与单用RALOX方案对晚期结直肠癌患者的应用效果。结果观察组患者客观缓解率、疾病控制率、中位无进展生存时间和总生存时间均显著高于对照组患者,治疗后血癌胚抗原(CEA)、糖类抗原(CA)199表达水平均显著低于对照组患者(P<0.05)。骨髓抑制、恶心/呕吐是最常见的不良反应,均以Ⅰ~Ⅱ级为主。观察组与对照组晚期结直肠癌患者不良反应发生率比较差异无统计学意义(P>0.05)。结论阿帕替尼联合RALOX方案对晚期结直肠癌的疗效确切,效果优于单用RALOX方案,且并未明显增加不良反应,可作为晚期结直肠癌患者的二线治疗方案推荐。Objective To investigate the effect of apatinib combined with RALOX(oxaliplatin+raltitrexed)in the treatment of advanced colorectal cancer.Methods Patients with advanced colorectal cancer who received apatinib combined with RALOX(observation group,n=39)or RALOX treatment alone(control group,n=39)in the Department of Gastroenterology of the 908th Hospital of Joint Logistics Support Force were enrolled in this study.The treatment effects of the two regimens were compared.Results The objective response rate,disease control rate,median progression-free survival time,and overall survival time of patients in the observation group were significantly higher than those in the control group.Additionally,blood CEA and CA199 expression levels were significantly lower after treatment in the observation group compared to the control group(P<0.05).Regarding safety,bone marrow suppression and nausea/vomiting were the most common adverse reactions,mainly classified as gradeⅠ-Ⅱ.There were no significant differences in the incidence of adverse reactions between the observation and control groups(P>0.05).Conclusions Apatinib combined with RALOX shows better efficacy than RALOX alone in patients with advanced colorectal cancer.Moreover,it does not significantly increase the incidence of adverse effects,making it a recommended second-line treatment option for patients with advanced colorectal cancer.

关 键 词：结直肠肿瘤 阿帕替尼 奥沙利铂 雷替曲塞 癌胚抗原 抗原 肿瘤相关 碳水化合物 无进展生存期 

分 类 号：R735.340.53[医药卫生—肿瘤]